FLT1 and other candidate fetal haemoglobin modifying loci in sickle cell disease in African ancestries

FLT1 和其他候选胎儿血红蛋白修饰基因位点在非洲裔镰状细胞病中的作用

阅读:1
作者:Ambroise Wonkam # ,Kevin Esoh # ,Rachel M Levine ,Valentina Josiane Ngo Bitoungui ,Khuthala Mnika ,Nikitha Nimmagadda ,Erin A D Dempsey ,Siana Nkya ,Raphael Z Sangeda ,Victoria Nembaware ,Jack Morrice ,Fujr Osman ,Michael A Beer ,Julie Makani ,Nicola Mulder ,Guillaume Lettre ,Martin H Steinberg ,Rachel Latanich ,James F Casella ,Daiana Drehmer ,Dan E Arking ,Emile R Chimusa ,Jonathan S Yen ,Gregory A Newby ,Stylianos E Antonarakis

Abstract

Known fetal haemoglobin (HbF)-modulating loci explain 10-24% variation of HbF level in Africans with Sickle Cell Disease (SCD), compared to 50% among Europeans. Here, we report fourteen candidate loci from a genome-wide association study (GWAS) of HbF level in patients with SCD from Cameroon, Tanzania, and the United States of America. We present results of cell-based experiments for FLT1 candidate, demonstrating expression in early haematopoiesis and a possible involvement in hypoxia associated HbF induction. Our study employed genotyping arrays that capture a broad range of African and non-African genetic variation and replicated known loci (BCL11A and HBS1L-MYB). We estimated the heritability of HbF level in SCD at 94%, higher than estimated in unselected Europeans, and suggesting a robust capture of HbF-associated loci by these arrays. Our approach, which involved genotype imputation against six reference haplotype panels and association analysis with each of the panels, proved superior over selecting a best-performing panel, evidenced by a substantial proportion of panel-specific (up to 18%) and a low proportion of shared (28%) imputed variants across the panels.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。